Figure 5 | Scientific Reports

Figure 5

From: High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer

Figure 5

Ganetespib responses in a panel of LuCaP organoids. (A) HSP90 inhibitor data from 110 compound high-throughput screen of 15 LuCaP PDX-derived organoid models. Data presented as fitted area under curve (AUC) for 10 points between 30,000-1.52 nM. (B) Ganetespib dose response assays on LuCaP organoids. Data presented as percent viability +/− SEM. (C) Western blot biomarker analysis of indicated LuCaP organoids treated with DMSO or 125 nM ganetespib (G) for 24 or 48 hours. Images are representative of a minimum of two assays (n = 2) and vertical white space between images indicates separate gels. (D) qPCR analysis of AR target genes expression in several LuCaP organoid models following 24 hour exposure to 125 nM ganetespib. Data displayed as expression relative to untreated control +/− SEM (n = 3).

Back to article page